RevOpsis and Kemwell Biopharma Form Strategic Partnership to Speed Up Novel Biologics Development

RevOpsis Therapeutics, a pioneering biopharmaceutical company focused on developing advanced ophthalmic therapies, has announced a strategic partnership with Kemwell Biopharma Pvt. Ltd., a prominent biologics contract development and manufacturing organization (CDMO). This strategic alliance aims to accelerate the development of RevOpsis' flagship candidate, RO-104, a groundbreaking tri-specific biologic designed to treat neovascular age-related macular degeneration (nAMD), which is a leading cause of blindness globally.

Kemwell Biopharma will be responsible for manufacturing RO-104. This innovative biologic targets three primary angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in nAMD. The unique tri-specific binding capability of RO-104 sets it apart as a first-in-class fully human monotherapy, potentially revolutionizing treatment for retinal vascular diseases.

Kemwell's expertise and established reputation in high-quality biologics manufacturing will be instrumental in this partnership. As India's first commercial facility adhering to current Good Manufacturing Practices (cGMP), Kemwell brings extensive experience in complex protein manufacturing to the table. This collaboration aims to leverage Kemwell's manufacturing proficiency and RevOpsis' innovative Rev-Mod platform to expedite the development of new multispecific biologics.

Dr. Ram Bhandari, Co-founder and Interim CEO of RevOpsis, highlighted the significance of this partnership. He emphasized that partnering with Kemwell is a critical step in advancing the development of RO-104 and other multispecific biologics in their pipeline. He noted that Kemwell's excellent track record in biologics manufacturing and efficiency in reducing timelines complements RevOpsis' proprietary Rev-Mod platform, ensuring the swift delivery of transformative therapies to patients.

Anurag Bagaria, CEO of Kemwell Biopharma, expressed enthusiasm about the collaboration. He pointed out that Kemwell's expertise in complex protein manufacturing combined with RevOpsis' innovative therapeutic approaches holds significant promise for advancing retinal vascular disease treatments. According to Bagaria, this strategic partnership underscores Kemwell's commitment to delivering high-quality biologics to patients in need.

This alliance provides a crucial biologics development solution for RevOpsis, enabling a rapid transition from pre-clinical activities to first-in-human clinical trials. By integrating RevOpsis' next-generation multispecific biologics platform with Kemwell's deep expertise in biologics development and manufacturing, the collaboration aims to streamline therapeutic discovery and expedite IND submission timelines. This efficient connection between preclinical efforts, process development, and clinical manufacturing is expected to significantly reduce the complexity and timelines associated with early GMP manufacturing processes.

RO-104, developed using the proprietary Rev-Mod platform, stands as RevOpsis' lead candidate. It is designed as a first-in-class fully human modular tri-specific biologic, targeting all three clinically validated dominant angiogenic pathways implicated in retinal vascular disease progression, including nAMD. RO-104 represents a significant advancement in the treatment of retinal vascular diseases, backed by extensive preclinical evidence demonstrating its intended efficacy and safety in established animal models. RO-104 is poised to redefine the standard of care for patients with nAMD.

The proprietary Rev-Mod Platform, RevOpsis' core technology, employs a modular 'plug-and-play' approach to expedite the discovery and development of multispecific biologics targeting a wide array of chronic diseases. The platform's vast library of nearly 30 billion fully human antibody components facilitates the rapid identification and assembly of multispecific product candidates. This enables efficient design of biologics to address unmet needs in major therapeutic areas, including ophthalmology, oncology, and immune-mediated diseases.

RevOpsis Therapeutics, founded in 2018, is a privately held company dedicated to revolutionizing ophthalmic therapies through its proprietary Rev-Mod Platform. With a team of leading physicians, scientists, and business leaders, RevOpsis is committed to advancing patient care by developing and commercializing groundbreaking treatments for chronic multifactorial diseases, ultimately aiming to improve disease management and extend disease remission.

Kemwell Biopharma, based in Bangalore, India, is a leading biologics CDMO providing services for both clinical and commercial needs. Kemwell's facilities include cGMP drug substance manufacturing suites, sterile fill and finish for drug product manufacturing, and development laboratories for process and analytical development of protein therapeutics. The company is currently involved in manufacturing commercial drug substances and products and has a robust history of supporting numerous R&D projects during the development and clinical phases for novel biologics and biosimilars.